Medical use of cannabis for glaucoma
The clinical utility of cannabis (sometimes referred to as marijuana or marihuana) for the treatment of glaucoma is limited by the inability to separate the potential clinical action from the undesirable neuropsychological and behavioural effects. The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of glaucoma due to the short duration of action, the incidence of undesirable psychotropic and other systemic side effects and the absence of scientific evidence showing a beneficial effect on the course of the disease. This is in contrast to other more effective and less harmful medical, laser and surgical modalities for the treatment of glaucoma.
Read the full policy statement from the Canadian Ophthalmological Society (COS) and the Canadian Glaucoma Society (CGS).
Recommendations from the Canadian Neuro-Ophthalmology Society regarding Neuro-Ophthalmology Care During the COVID-19 Pandemic
May 29, 2020 As we transition into a new normal...
COS – Ophthalmic Surgery Prioritization
Ophthalmic Surgery Prioritization Updated, May 28, 2020 Hospitals and ambulatory...
Checklist on Reopening Ophthalmology Clinics during COVID-19
Checklist on Reopening Ophthalmology Clinics during COVID-19 May 15, 2020...
Can Ophthal Society's Twitter via Twitter Web Client
Redirecting to a Third-Party Website
You are now temporarily leaving the Practice Resource Centre. Clicking the button below will open a third-party website in a new browser tab. The website you are being redirected to is published by a third party and as such, its content is not under the control of the COS.
(If you do not wish to proceed, you can cancel this action by clicking the “X” in the corner of this message window)